High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
No studies have examined the relationship between endogenous polyunsaturated fatty acids (PUFAs) levels and treatment response to PUFAs. We conducted a 12-week, double-blind, placebo-controlled trial comparing the effects of high-dose eicosapentaenoic acid (EPA, 1.2 g) and placebo on cognitive function (continuous performance test) in n = 92 youth (age 6–18-years-old) with Attention Deficit Hyperactivity Disorder (ADHD). Blood erythrocytes PUFAs were measured before and after treatment, to examine the effects of baseline endogenous EPA levels on treatment response and the effects of EPA treatment on PUFAs levels. Secondary measures included other ADHD symptoms, emotional symptoms, and levels of plasma high-sensitivity c-reactive protein (hs-CRP) and brain-derived neurotrophic factor (BDNF). Overall, EPA group improved more than placebo group on focused attention (variability, Effect size (ES) = 0.38, p = 0.041); moreover, within youth with the lowest baseline endogenous EPA levels, EPA group improved more than placebo group in another measure of focused attention (hit reaction time, HRT, ES = 0.89, p = 0.015) and in vigilance (HRT interstimulus interval changes, HRTISIC, ES = 0.83, p = 0.036). Interestingly, EPA group improved less than placebo group in impulsivity (commission errors), both overall and in youth with the highest baseline EPA levels, who also showed less improvement in other ADHD and emotional symptoms. EPA increased blood erythrocytes EPA by 1.6-fold but not DHA levels, and did not affect hs-CRP and BDNF plasma levels. In conclusion, EPA treatment improves cognitive symptoms in ADHD youth, especially if they have a low baseline endogenous EPA level, while youth with high EPA levels may be negatively affected by this treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30269-4 · Cited by 1,716
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Burdge, G. C., & Wootton, S. A. (2002) · British Journal Of Nutrition · doi:10.1079/bjn2002689 · Cited by 812
Bloch, M. H., & Qawasmi, A. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.06.008 · Cited by 417
Chang, J. P.-C., Su, K.-P., Mondelli, V., & Pariante, C. M. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.160 · Cited by 248
Self-citationGrosso, G., Micek, A., Marventano, S., Castellano, S., Mistretta, A., Pajak, A., & Galvano, F. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.08.011 · Cited by 244
Vaisman, N., Kaysar, N., Zaruk-Adasha, Y., Pelled, D., Brichon, G., Zwingelstein, G., & Bodennec, J. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.5.1170 · Cited by 160
Lin, P.-Y., Mischoulon, D., Freeman, M. P., Matsuoka, Y., Hibbeln, J., Belmaker, R. H., & Su, K.-P. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.111 · Cited by 145
Self-citationAmiri, A., Torabi Parizi, G., Kousha, M., Saadat, F., Modabbernia, M.-J., Najafi, K., & Atrkar Roushan, Z. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.07.018 · Cited by 58
Cited by
Importance of EPA and DHA Blood Levels in Brain Structure and Function
von Schacky, C. (2021) · Nutrients · doi:10.3390/nu13041074 · Cited by 174
“More recently, a 12-week trial with EPA found EPA, but not DHA, increased in red cells, which improved cognitive symptoms more in participants with low baseline EPA than in participants high baseline EPA in red cells [76].”
BackgroundAcute EPA-induced learning and memory impairment in mice is prevented by DHA
Liu, J.-H., Wang, Q., You, Q.-L., Li, Z.-L., Hu, N.-Y., Wang, Y., Jin, Z.-L., Li, S.-J., Li, X.-W., Yang, J.-M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19255-1 · Cited by 77
Omega-3 fatty acids in the psychological and physiological resilience against COVID-19
Chang, J. P.-C., Pariante, C. M., & Su, K.-P. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102177 · Cited by 36
Self-citationYang, L. L., Stiernborg, M., Skott, E., Söderström, Å., Giacobini, M., & Lavebratt, C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.10.005 · Cited by 29
Metadata
- Authors
- Chang, J. P.-C., Su, K.-P., Mondelli, V., Satyanarayanan, S. K., Yang, H.-T., Chiang, Y.-J., Chen, H.-T., & Pariante, C. M.
- Venue
- Translational Psychiatry
- Published
- 2019-11-20
- Volume
- 9
- Issue
- 1
- Pages
- 303-303
- ISSN
- 2158-3188 (ISSN-L)
- OpenAlex
- W2983464518
- Cited by
- 90
- References
- 10
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. https://app.cochat.ai/papers/10.1038/s41398-019-0633-0
- The paper
- Chang, J. P.-C., Su, K.-P., Mondelli, V., Satyanarayanan, S. K., Yang, H.-T., Chiang, Y.-J., Chen, H.-T., & Pariante, C. M. (2019). High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry. https://doi.org/10.1038/s41398-019-0633-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.